Cadila Healthcare divests animal health business: ICICI Securities
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Subscribe To Our Newsletter & Stay Updated